APA

Bostwick D. G., Burke H. B., Wheeler T. M., Chung L. W., Bookstein R., Pretlow T. G., Nagle R. B., Montironi R., Lieber M. M. & Veltri R. W. (19950210). The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. : Journal of cellular biochemistry. Supplement.

Chicago

Bostwick D G, Burke H B, Wheeler T M, Chung L W, Bookstein R, Pretlow T G, Nagle R B, Montironi R, Lieber M M and Veltri R W. 19950210. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. : Journal of cellular biochemistry. Supplement.

Harvard

Bostwick D. G., Burke H. B., Wheeler T. M., Chung L. W., Bookstein R., Pretlow T. G., Nagle R. B., Montironi R., Lieber M. M. and Veltri R. W. (19950210). The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. : Journal of cellular biochemistry. Supplement.

MLA

Bostwick D G, Burke H B, Wheeler T M, Chung L W, Bookstein R, Pretlow T G, Nagle R B, Montironi R, Lieber M M and Veltri R W. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. : Journal of cellular biochemistry. Supplement. 19950210.